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Abstract: The sympathetic nervous system is involved in regulating various cardiovascular 
parameters including heart rate (HR) and HR variability. Aberrant sympathetic nervous system 
expression may result in elevated HR or decreased HR variability, and both are independent 
risk factors for development of cardiovascular disease, including heart failure, myocardial 
infarction, and hypertension. Epidemiologic studies have established that impaired HR control 
is linked to increased cardiovascular morbidity and mortality. One successful way of decreasing 
HR and cardiovascular mortality has been by utilizing β-blockers, because their ability to 
alter cell signaling at the receptor level has been shown to mitigate the pathogenic effects of 
sympathetic nervous system hyperactivation. Numerous clinical studies have demonstrated 
that β-blocker-mediated HR control improvements are associated with decreased mortality 
in postinfarct and heart failure patients. Although improved HR control benefits have yet to 
be established in hypertension, both traditional and vasodilating β-blockers exert positive HR 
control effects in this patient population. However, differences exist between traditional and 
vasodilating β-blockers; the latter reduce peripheral vascular resistance and exert neutral or 
positive effects on important metabolic parameters. Clinical evidence suggests that attainment 
of HR control is an important treatment objective for patients with cardiovascular conditions, 
and vasodilating β-blocker efficacy may aid in accomplishing improved outcomes.
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Introduction
Numerous studies have reported that increased heart rate (HR) is a predictor of 
cardiovascular mortality in healthy people, those who have had a myocardial 
infarction (MI), and in patients with heart failure (HF).1 Increased HR is recognized 
as a negative prognostic factor independent of other clinical parameters, including left 
ventricular function.1 The increased mortality observed with an increased HR may be a 
consequence of the deleterious sympathovagal imbalance that can be characterized by 
sympathetic nervous system predominance, vagal depression, or the combined impact 
of this dysregulation on cardiovascular function.1,2 Elevated HR increases cardiac output 
(short term) and myocardial oxygen consumption, while simultaneously reducing time 
of diastole and myocardial blood supply, conditions that favor the development of 
myocardial ischemia and arrhythmias in ischemic areas.1
Blockade of β-adrenergic receptors is part of the combined medical prevention 
of cardiovascular disease.3,4 β-Blockers have been efficacious and beneficial in 
the treatment of various cardiovascular disease states, including angina, HF, MI, 
and ventricular arrhythmias.5 Randomized controlled clinical studies consistently Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
388
Feldman et al
demonstrate that β-blockers reduce sudden cardiac death 
by 30% to 50% in patients with coronary artery disease and 
HF.6 The clinical benefits of β-blockers have been attributed 
to their ability to antagonize β-adrenergic receptors in the 
heart and the periphery.7 Traditional β-blockers (eg, atenolol 
and propranolol), which target either β1- (cardioselective) 
or β1- and β2-adrenergic receptors (nonselective), decrease 
BP primarily via a reduction in HR and cardiac output, but 
do not appreciably affect peripheral vascular resistance.5 
Acutely, uptitration of β-blockers can decrease cardiac output 
and increase vascular tone, which may exert a detrimental 
effect on renal perfusion and decrease patient drug tolerabil-
ity, while exacerbating glucose and lipid metabolism.8,9 In 
addition, these metabolic perturbations may lead to further 
vascular complications by adversely affecting endothelial 
function and promoting the development or progression of 
diabetes.9,10
Vasodilatory β-blockers (eg, carvedilol, labetalol, and 
nebivolol) and those that provide more complete adrenergic 
blockade may, in part, mediate vasodilation via blockade of 
α1-adrenergic receptors or increased endothelium-derived 
nitric oxide release, which may lead to a reduction in total 
peripheral vascular resistance.9 This review will examine the 
data, including recent analyses from the large cardiovascular 
trials, related to adrenergic blockade, HR control, and 
its impact on outcomes across the cardiovascular disease 
spectrum (ie, patients who have had a MI or who have HF 
or hypertension).
Heart rate and heart rate variability
Heart rate is not a static hemodynamic parameter but 
instead changes over time in response to physical and 
mental demands. Heart rate is normally determined by 
spontaneous and periodic depolarizations of the sinoatrial 
node, the frequency of which is modulated by the sympathetic 
and parasympathetic divisions of the autonomic nervous 
system, the intrinsic cardiac nervous system, reflexes, and 
respiration. These neural systems also partially control 
cardiac contractility and conduction of electrical activity 
through the heart. As a result, HR (chronotropism), 
contractility (inotropism), and conduction (dromotropism) 
are adjusted to meet the changing needs of the body. Aberrant 
sympathetic activation has been implicated as part of the 
sequelae consistent with the development of HF, MI, and 
hypertension.11,12 Profoundly elevated sympathetic activity 
for an extended period accompanied by parasympathetic 
withdrawal may result in chronically elevated HR, as well as 
neurohormonal stimulation, and is associated with a decreased 
threshold for ventricular fibrillation. This upregulation of 
the sympathetic nervous system and increased adrenergic 
activation is also associated with pathologic remodeling, 
myocyte apoptosis, and a dysregulation of calcium handling 
that leads to myocardial ischemia, a decrement in contractile 
function, and an increased risk of ventricular arrhythmias.13,14 
Due to the correlative linkage of HR and sympathetic nervous 
system outflow, HR control may be used as a surrogate for 
sympathetic nervous system activity.
Optimal heart rate
Heart rate varies between individuals, and in a resting 
individual HR may vary according to time of day, physical 
conditioning, environmental influences, and sympathetic 
nervous system vagal tone. However, recent reports sug-
gest that HR should generally be maintained substantially 
below the traditionally defined tachycardia threshold of 
90 to 100 beats/minute.15 A continuous linear increase 
in cardiovascular risk has been noted in patients whose 
HR exceeds 60 beats/minute.16,17 Results from the Global 
Utilization of Streptokinase and TPA for Occluded Arteries 
(GUSTO-1) study suggest that an increased risk of cardiovas-
cular disease may even exist when HR is ,60 beats/minute.18 
Increases in HR exceeding 10 beats/minute are associated 
with a 14% increase in cardiovascular mortality and a 20% 
increase in total mortality in patients with hypertension.19 
In the general population, the mortality risk is increased 
three-fold in individuals with a HR of 90 to 99 beats/minute 
compared with individuals with a HR # 60 beats/minute.20
Heart rate and mortality
Numerous studies report that a significant association 
exists between resting HR and cardiovascular and 
all-cause mortality in the general population, as well as 
among patients with cardiovascular disease. Epidemiologic 
studies involving approximately 30,000 individuals over a 
period of five to 36 years revealed an inverse relationship 
between HR and survival in the general population.20–25 
The risk of coronary artery disease, stroke, death due to 
noncardiovascular diseases, and total mortality increased 
with higher HR. Among 5713 healthy male volunteers with-
out known or suspected cardiovascular disease who were 
observed for an average of 23 years, cardiovascular and 
all-cause mortality from acute MI increased with progres-
sive elevations in resting HR.17 This independent variable 
remained significant after adjustment for exercise capacity, 
age, diabetes, systolic arterial pressure, body mass index, 
level of physical activity, and other factors. The relationship Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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was most apparent for sudden death (Figure 1).17 In a 
study of 10,267 patients with acute coronary syndromes, 
mortality at 30 days and 10 months progressively increased 
with increasing HR (P , 0.001).26 Similarly, all-cause and 
cardiovascular mortality were directly related to resting HR 
at study entry in 24,913 patients with suspected or proven 
coronary artery disease who participated in the Coronary 
Artery Surgery Study (CASS) registry for a period of 
15 years (P , 0.0001; Figure 2).15,16 The predictive capacity 
of HR was independent of concomitant hypertension, diabe-
tes, smoking, left ventricular ejection fraction, and number 
of diseased coronary vessels.
Because the association between HR and mortality is 
well known, resting HR is currently included in risk assess-
ment indices for patients with acute coronary syndromes 
(eg, the Global Registry of Acute Coronary Events risk 
prediction score)27 and acute MI (eg, the Gruppo Italiano 
per lo Studio della Sopravivenza nell’Infarto Miocardico 
Prevenzione risk assessment model28 and the Thrombolysis 
in Myocardial Infarction Risk Score29). However, HR is 
not included in some of the more widely used indices for 
cardiovascular risk assessment, including the Copenhagen 
Risk Score30 and the European SCORE project,31 which 
indicates that HR is not universally accepted as a prognos-
tic factor and a potential therapeutic target in patients with 
cardiovascular disease.
Heart rate variability
Heart rate variability (HRV) refers to the beat-to-beat 
difference or R-R interval change in the intrinsic rhythm 
of the heart.32 Assessment of HRV may provide a surrogate 
measure of cardiac health, as defined by the degree of equi-
librium between sympathetic and parasympathetic (vagus 
nerve) activity.33 HRV can be assessed by time or frequency 
domain indices.32 Time domain measures are based on the 
amount of time in milliseconds in the beat-to-beat intervals 
of the heart or on the differences between the normal beat-
to-beat intervals.33 Frequency domain measures of HRV 
provide information about the frequency distribution of the 
components of HRV using power spectral density analysis.33 
Nonlinear dynamic analysis (eg, Poincaré plots) may also be 
used to quantify HRV , but the clinical utility of this method 
has not been fully established.32 As discussed in subsequent 
sections, numerous studies have demonstrated the positive 
prognostic power of reduced HRV to predict all-cause mor-
tality, sudden cardiac death, and cardiac events in patients 
who have experienced an MI, as well as in patients who have 
HF or hypertension.
Heart rate control in heart failure
HF is frequently associated with a decreased threshold 
for ventricular fibrillation, as well as an increased risk of 
other malignant arrhythmias and sudden cardiac death. 
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Figure 1 Heart rate and mortality in healthy individuals: Relative risk of death from any cause, nonsudden death from myocardial infarction (Mi), and sudden death from Mi in 
5713 people without known or suspected heart disease. Differences among quintiles with respect to risk of death from any cause, P , 0.001; nonsudden death from cardiac 
causes, P = 0.02; sudden death from cardiac causes, P , 0.001. Copyright @ 2005. Massachusetts Medical Society. All rights reserved. Reprinted with permission from Jouven 
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Increased HR (eg, atrial fibrillation with a rapid ventricular 
rate or multiple premature contractions) may contribute to 
the development of HF and is also associated with a poor 
prognosis in patients with HF.34 In the normal heart, a 
stepwise increase in contractility develops as HR increases. 
Ninety percent of patients with HF die of cardiovascular 
causes.35   Approximately half of these patients die from pro-
gressive, advanced disease and the remaining patients die 
suddenly, most frequently because of arrhythmia despite a 
perceivably stable clinical condition. Sudden cardiac death 
occurs most frequently in patients in New York Heart Asso-
ciation Functional Class II or III. Risk factors for sudden 
cardiac death include elevated resting HR, and reduced HRV 
and left ventricular ejection fraction.36
Numerous studies have established a relationship between 
reduction in HR and improved survival of patients with HF 
who are receiving β-blocker therapy (Figure 3).37 In a recent 
meta-analysis of 35 studies of patients with chronic systolic HF 
(n = 22,926), a strong correlation was observed between HR 
and annualized all-cause mortality (P = 0.004) and between 
change in HR and change in left ventricular ejection fraction 
(P , 0.001).38 As a result, it was suggested that the HR-
lowering effect of β-blockers was a major contributor to the 
clinical benefit associated with these agents. In a study of 152 
patients with HF who were receiving β-blocker therapy, greater 
reductions in HR were associated with better clinical outcomes 
for patients overall, and higher β-blocker doses provided 
additional clinical benefits among patients with persistently 
elevated HR.39 These results suggest that the magnitude of 
reduction in HR may be more important than achieving the 
target dose of β-blocker therapy in patients with HF.38,39 In the 
Cardiac Insufficiency BIsoprolol Study (CIBIS), treatment of 
557 patients with bisoprolol reduced HR by approximately 15 
beats/minute relative to placebo (P , 0.001), and HR change 
was the most powerful predictor of survival (P , 0.01).40 In the 
larger CIBIS II study (n = 2539), baseline HR and HR change 
were both significant predictors of mortality (P # 0.005).41 The 
most favorable prognosis occurred in patients with the lowest 
baseline HR and with the greatest HR reduction, conditions 
which were encountered more frequently in the bisoprolol 
group than in the placebo group.
The Carvedilol Post-Infarct Survival Control in Left 
Ventricular Dysfunction (CAPRICORN) trial evaluated 
patients with left ventricular dysfunction or HF after a 
  myocardial infarction (n = 1959),42 whereas the Carve-
dilol Prospective Randomized Cumulative Survival 
(COPERNICUS) trial enrolled only patients with severe HF 
(n = 2289).43 The Metoprolol CR/XL Randomized Interven-
tion Trial in Congestive Heart Failure (MERIT-HF) enrolled 
patients with New York Heart Association Class II–IV HF 
with an ejection fraction ,40% (n = 3991).44 These trials 
each independently demonstrated benefits of β-blockade 
in patients with HF throughout a large spectrum of dis-
ease. Additionally, the Carvedilol or Metoprolol (tartrate) 
European Trial (COMET; n = 3029) may suggest that 
nonselective neurohumoral blockade has an additional ben-
efit compared with selective β1-blockade.45 Consequently, 
adrenergic-receptor pathophysiology and thereafter specific 
signal transduction pathways may underlie the benefit of 
using specific β-blockers.46 Although studies using one of 
the three β-blockers approved for HF in the US (carvedilol, 
metoprolol succinate, or bisoprolol) have demonstrated 
benefit in patients with HF, nebivolol has also received 
approval in Europe for the treatment of mild-to-moderate 
HF in patients $70 years of age.47 Nebivolol is a β1-selective 
β-blocker without α1-adrenergic receptor blocking activity. 
Nebivolol, which is approved for the treatment of hyperten-
sion in the US, has a neutral effect on metabolic parameters 
in patients with hypertension.48 Nebivolol has been shown to 
reduce BP and HR to a similar extent as atenolol at one-tenth 
of the dose.49 More importantly, the hemodynamic effect 
observed with nebivolol treatment better preserved cardiac 
output by decreasing peripheral vascular resistance and 
increasing stroke volume compared with atenolol.50
H
a
z
a
r
d
 
r
a
t
i
o
Heart rate (bpm)
1.4
Overall mortality
Cardiovascular mortality
1.2
1
0.8
<63 63–70 71–76 77–82 >82
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Comparison of bisoprolol, carvedilol, and nebivolol in 
patients with HF demonstrated that each agent decreased 
HR to a similar extent.51 Additionally, exercise capacity 
increases during β-blocker therapy. For example, among 16 
healthy male volunteers, HR during exercise decreased by 
14% in the bisoprolol group, 15% in the carvedilol group, 
and 13% in the nebivolol group (P , 0.05).51 Additionally, 
the effect of carvedilol and nebivolol on exercise capacity 
were compared in a 12-month study of patients with nonis-
chemic dilated cardiomyopathy.52 Exercise duration improved 
significantly in both groups of patients (P = 0.01), although 
patients treated with nebivolol experienced an initial decrease 
in exercise capacity over the first three months.52 In patients 
with HF, reduction in peak VO2 is associated with left ven-
tricular systolic dysfunction and increased neurohormonal 
response. Treatment with carvedilol improved left ventricular 
systolic function, exercise tolerance (at 12 months, exercise 
was prolonged by 143.9 sec; P = 0.001), and peak oxygen 
consumption as well as significant reductions in brain natri-
uretic peptide, endothelin-1, and associated cytokines (ie, 
interleukin-6 and tumor necrosis factor-α).53 In a recent 
analysis of 47 randomized studies of HF, a significant increase 
in the six-minute walk test was observed in three of 17 stud-
ies that involved β-blocker therapy.54 Similar to the results 
of exercise treadmill tests, patients who received β-blocker 
therapy for more severe HF experienced greater improve-
ments in the six-minute walk test compared with those 
having milder HF. Therefore, administration of β-blocker 
therapy to patients with HF is associated with improved HR 
control, improvement in clinical functioning, and reduction in 
mortality and hospitalization risk. The benefits of β-blocker 
therapy are clear, ie, mortality and HF hospital admissions 
are reduced by approximately one-third when eligible patients 
receive β-blocker therapy.55,56
Chronotropic incompetence  
in heart failure
Patients with HF experience severe chronic exercise 
intolerance. Although the pathophysiology of exercise intoler-
ance is not completely understood, chronotropic incompe-
tence, defined as an impaired capacity to increase HR during 
exercise, and diastolic dysfunction are important determi-
nants of this condition.57 Chronotropic incompetence occurs 
in .70% of patients with advanced HF and is believed to 
arise as a result of β-receptor desensitization and impaired 
norepinephrine release.58 Risk factors for the develop-
ment of chronotropic incompetence include increased left 
ventricular mass, enlarged cavity size, and depressed systolic 
function.59 Chronotropic incompetence is predictive of mor-
tality and coronary artery disease risk, even after adjusting 
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for age, physical fitness, and other standard cardiovascular 
risk factors.60 Although some studies have reported that 
chronotropic incompetence was more common in patients 
taking β-blockers,61 β-blockade has been reported to have 
a minimal effect on the association between chronotropic 
incompetence and cardiovascular mortality.62,63 At doses 
,10 mg, nebivolol did not attenuate the exercise-induced 
increase in HR, thereby suggesting that nebivolol may 
mitigate the risk of chronotropic incompetence suggested 
to occur with β-blockade.64 Similarly, carvedilol dose did 
not affect the HR dynamics during treadmill exercise testing 
among patients with HF who were stratified by resting HR 
(#60 beats/minute or .60 beats/minute).65 In a trial com-
paring the β1 effects of metoprolol succinate and carvedilol, 
carvedilol did not attenuate exercise-induced HR to the same 
degree as metoprolol.66 Cardiac pacing may be required to 
restore chronotropic competence and exercise capacity in 
patients with persistent bradycardia, as well as allowing for 
continued β-blocker therapy.67 There is a developing body 
of literature regarding the treatment of diastolic HF and 
chronotropic incompetence, but the clinical relevance of this 
information has yet to be determined.
Heart rate control  
after myocardial infarction
Increased HR in patients with atherosclerosis may impair 
the stability of coronary plaques because of repetitive 
changes in BP that induce mechanical stress. Increased HR 
(.80 beats/minute) is associated with more plaque ruptures 
compared with lower HR in patients with coronary artery 
disease (n = 106).68 HRs in patients following MI are higher 
than in patients who have not experienced an acute event.69 
Consequently, HR has been identified as an independent risk 
factor for the development of plaque rupture. In addition, HR 
but not HRV was identified as an independent prognostic 
indicator of mortality in a study of 366 patients after MI 
(P , 0.001).70 However, a subsequent study reported that 
decreased HRV and increased randomness of HR shortly after 
MI are independent risk factors for mortality in this patient 
population.71 Similar to HF, increased HR or reduced HRV are 
associated with increased cardiovascular mortality in patients 
after MI.32 A meta-analysis of the GISSI-2 and GISSI-3 trials 
that included approximately 20,000 patients demonstrated 
that inhospital mortality rates after MI increased from 3% 
for patients with HR ,60 beats/minute on admission to 10% 
for patients with HR .100 beats/minute on admission.72 
Furthermore, higher HR at hospital discharge correlated with 
increased mortality rates after one year.69
Traditional β-blockers exert beneficial effects on HR 
and HRV and improve mortality rates in patients who 
have experienced an MI. Administration of β-blockers to 
1427 patients within six hours of the onset of MI symptoms 
resulted in a mean reduction in infarct size that was directly 
proportional to the mean reduction in HR (P , 0.001).73 
Furthermore, a significant association was reported between 
reduction in HR and reduction in mortality in 11 long-term 
β-blocker studies that involved more than 16,000 patients 
(Figure 4; r = 0.60; P , 0.05).73 The Norwegian Timolol 
study reported similar results in that β-blocker-mediated HR 
reductions in patients who had experienced an MI were a sig-
nificant predictor of overall mortality.74 Compared with placebo, 
timolol treatment was associated with a 42% reduction in overall 
mortality compared with placebo (P , 0.001); in logistic regres-
sion analysis, HR during follow-up remained predictive but 
treatment did not, suggesting that the beneficial effect of timolol 
on mortality could be ascribed to its effect on HR. HRV was also 
significantly improved among 28 patients who were treated with 
atenolol or metoprolol tartrate for six weeks after an acute MI 
(P # 0.01); trends toward lower HR were also observed in both 
treatment groups.2 Similarly, treatment of 30 patients who were 
stable following an MI with atenolol or metoprolol controlled-
release (succinate) for six weeks decreased HR (P , 0.001) and 
increased HRV .75 Propranolol treatment was also associated with 
significantly greater improvements in HRV after an acute MI 
compared with placebo (P , 0.05; n = 184).76
Similar to the traditional β-blockers, vasodilating 
β-blockers exert beneficial effects on HR and HRV in 
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patients who have experienced an MI. Carvedilol produced 
reductions in HR relative to placebo in 151 patients with 
an acute MI (P , 0.0001).77 Labetalol, a nonselective 
β-blocker that targets α1-, β1-, and β2-adrenergic receptors, 
is used for the treatment of hypertension of all severities and 
during hypertensive emergencies.78,79 When given acutely, 
labetalol decreases peripheral vascular resistance and BP 
but may have limited effects on HR and cardiac output.80 
In another study, administration of labetalol to 32 patients 
with sustained elevations in systemic arterial pressure after 
a recent MI resulted in significant reductions in HR relative 
to pretreatment levels (P , 0.01).81 Nebivolol and atenolol 
both decreased HR in patients who had ischemic heart disease 
and a previous MI (n = 40); however, nebivolol maintained 
cardiac output and improved ejection fraction (P , 0.05).82 
The relationship between improved HR control and decreased 
mortality has not been assessed among patients who have 
been treated with vasodilating β-blockers after MI.
Heart rate control in hypertension
In patients with hypertension, sympathetic nervous system 
overactivity increases HR, contributing to cardiac output 
and raised BP. The association between increased HR and 
the development of hypertension was demonstrated in the 
HARVEST (Hypertension and Ambulatory Recording 
VEnetia STudy) trial, which revealed a strong linkage between 
elevated HR and increases in BP among patients with Stage 1 
hypertension.83 Patients whose HR was persistently elevated 
during the six-year study period had a two-fold higher risk of 
developing hypertension compared with patients with normal 
HR (n = 796). In patients with hypertension, normal sinus 
rhythm, and cardiovascular risk factors (n = 18,900), increasing 
HR from 81 to 119 beats/minute was associated with an 
increasing proportion of patients with microalbuminuria (63% 
to 69%, respectively; P , 0.0001).84 Elevated HR is also an 
independent predictor of microalbuminuria, a predictor for 
cardiovascular events, and an indicator of renal impairment in 
patients with hypertension (n = 18,900).84 In addition, greater 
impairment of HRV responsiveness to autonomic challenge 
was observed in patients with hypertension compared with a 
normotensive group (n = 40).85 Increased HR generally results 
in a poor prognosis for patients with hypertension. The rate 
of complications caused by cardiovascular disease as well as 
total mortality in patients with hypertension increased two-fold 
when HR increased by 40 beats/minute (n = 4530).86
The importance of lowering systemic vascular resistance 
and increasing tissue perfusion in patients with hypertension 
is well recognized, given that clinical evidence has established 
an association between impairment of microcirculation and 
development of end organ damage.87,88 Consequently, a goal 
of hypertension management is effective BP reduction while 
maintaining tissue perfusion. Traditional β-blockers reduce 
BP via decreased cardiac output but do not directly affect 
central aortic pressure or peripheral resistance, although a 
slight compensatory increase in peripheral resistance may 
occur.9 Administration of the traditional β-blocker, atenolol, 
to patients with hypertension significantly reduced HRV 
compared with placebo or losartan (P , 0.05).89,90 HR and 
BP at rest and during exercise was decreased in 10 patients 
with mild to moderate hypertension who received atenolol 
therapy for five years; however, systemic vascular resistance 
was elevated and cardiac output remained depressed com-
pared with pretreatment levels.91 Similar results have also 
been reported using 10 different traditional β-blockers.9 
Therefore, although traditional β-blockers lower BP, they do 
not appear to normalize cardiac hemodynamics in patients 
with hypertension. In addition, traditional β-blockers are 
associated with an increased risk for the development of 
abnormalities in metabolic parameters (eg, diabetes or 
endothelial dysfunction) or stroke compared with other 
antihypertensive agents.92–94
Vasodilatory β-blockers reduce BP via the lowering of 
peripheral vascular resistance and only slightly decreased in 
cardiac output; decreases in central aortic pressure have also 
been observed with vasodilatory β-blockers.79,95 In contrast 
with traditional β-blockers, carvedilol was shown to maintain 
cardiac output, decrease vascular resistance, and decrease 
HR to a lesser extent.96 A once-daily formulation of the 
vasodilatory β-blocker carvedilol controlled-release was 
administered to 320 patients with hypertension, resulting in 
greater reductions in HR (Figure 5) and 24-hour diastolic 
BP compared with placebo (P # 0.001).97 In the Glycemic 
Effects in Diabetes Mellitus: Carvedilol-Metoprolol 
Comparison in Hypertensives (GEMINI) study of 1235 
patients with hypertension and Type 2 diabetes mellitus, 
reductions in diastolic BP were similar in the carvedilol 
and metoprolol tartrate treatment groups (10.0 ± 0.4 and 
10.3 ± 0.3 mmHg, respectively). At mean doses required 
to achieve target BP (carvedilol 35 mg/day; metoprolol 
256 mg/day), both agents effectively reduced HR, although 
decreases were less among carvedilol- versus metoprolol-
treated patients (6.7 ± 0.4 versus 8.3 ± 0.4 beats/minute, 
respectively; P , 0.001).98 Of clinical importance, carvedilol 
demonstrated neutral or positive effects on glycemic control 
and lipid metabolism in analyses of the GEMINI study. After 
six weeks of treatment, once-daily nebivolol reduced HR by Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
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10.6 ± 10.3 beats/minute, systolic BP by 29 ± 17 mmHg, 
and diastolic BP by 16 ± 10 mmHg in an observational study 
of 6376 patients with hypertension.99 Patients with higher 
initial values experienced greater reductions in HR and BP 
compared with patients having moderately elevated initial 
values.99 In other clinical trials, nebivolol reduced vascular 
resistance and improved endothelial function in patients with 
hypertension, and also lowered the levels of the inflamma-
tory marker, high-sensitivity C-reactive protein, in healthy 
volunteers who smoked cigarettes.100,101
The clinical relevance of β-blocker-mediated HR control to 
long-term clinical outcomes is less clear in hypertension than 
in HF or after MI. However, it is clear that reducing peripheral 
vascular resistance with a vasodilatory β-blocker is a beneficial 
mechanism to patients with hypertension, ie, a state of inher-
ently elevated peripheral vascular resistance. In addition, 
vasodilating β-blockers maintain cardiac output but decrease 
peripheral vascular resistance, which improves peripheral blood 
flow. Improved blood flow is a major contributing factor to the 
more favorable tolerability and metabolic profiles of vasodilat-
ing β-blockers compared with traditional β-blockers.48,98
Recently, the use of β-blockade in essential hypertension 
has been called into question. Bangalore et al report increased 
cardiac events in hypertensive patients being treated with 
β-blockade.102 A lower HR achieved from β-blockade 
compared with other antihypertensives or placebo in a 
meta-analysis of over 34,000 patients with hypertension 
was associated with an increase in all-cause mortality, car-
diovascular mortality, MI, stroke, and HF. One caveat to this 
study, however, is that 78% of those studied were prescribed 
atenolol, and it has been suggested that atenolol, and not 
β-blockade itself, was the cause. The results were certainly 
provocative, and clearly additional testing needs to be con-
ducted to determine whether this is a class effect or an effect 
based on receptor specificity.46
Conclusion
An elevated or invariant HR is associated with the 
development of complications or various cardiovascular 
diseases including HF, MI, and hypertension. Patients with 
impaired HR control are at increased risk for all-cause and 
cardiovascular   mortality, especially sudden cardiac death. As 
a result, HR should be included among the major risk factors 
for cardiovascular disease and should be used to establish 
individual cardiovascular risk profiles. Epidemiologic studies 
have demonstrated that β-blockers improve HR control and 
decrease mortality in patients with cardiovascular disease. 
Clinical evidence has established a clear relationship between 
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improved HR control and decreased mortality in patients 
who have had an MI or who have HF. Although HR is an 
important contributor to the development of hypertension, 
a definite association between improved HR control and 
decreased mortality has yet to be established in this patient 
population. However, the importance of decreased peripheral 
vascular resistance while maintaining tissue perfusion is well 
recognized in patients with certain cardiovascular conditions, 
such as hypertension. Traditional β-blockers do not decrease 
but may in fact increase peripheral vascular resistance dur-
ing long-term treatment. In contrast, vasodilating β-blockers 
reduce peripheral vascular resistance and maintain cardiac 
output. Consequently, vasodilating β-blockers are an appro-
priate treatment option for patients with cardiovascular 
disease who are at high risk of sudden cardiac death, HF, 
or coronary artery disease, and for those with concordant 
comorbidities, including diabetes and peripheral vascular 
disease.
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